EMA Authorised: Spravato (esketamine hydrochloride) — Janssen-Cilag International NV

View source ↗

Summary

The EMA authorised Spravato (esketamine hydrochloride) for depressive disorders, with Janssen-Cilag International NV as the marketing authorization holder.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Major Depressive Disorder

Drugs mentioned

• SPRAVATO (ESKETAMINE HYDROCHLORIDE)

Snippet

Status: Authorised. Therapeutic area: Depressive Disorder. MAH: Janssen-Cilag International NV. Decision date: 12/12/2024